23 Sep 2022
We are pleased to announce the publication of a new paper by our clinical partners at Stanford University in the Journal of Allergy and Clinical Immunology.
Prof. Rosa Bacchetta and her team are using Epimune's technology for epigenetic quantification of regulatory T cells (Treg) to monitor patients with IPEX syndrome (Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked).
IPEX syndrome is a severe congenital systemic autoimmune disorder with refractory diarrhea, endocrinopathies, skin symptoms, and tendency to infection. It is one of the autoimmune polyendocrine syndromes (APS) (source).
Prof. Bacchetta and her team were able to show that epigenetic analysis of Treg is suitable for monitoring the course of the disease in patients with IPEX and for early therapeutic intervention.
Epimune’s technology platform roots in the identification of the so called T-reg Specific De-methylated Region (TSDR) of the FOXP3 locus for the highly specific quantification of regulatory T-cells (more information HERE).